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Objective To compare the effectiveness of a hysteroscopic niche
resection versus no treatment in women with postmenstrual
spotting and a uterine caesarean scar defect.
Design Multicentre randomised controlled trial.
Setting Eleven hospitals collaborating in a consortium for
women’s health research in the Netherlands.
Population Women reporting postmenstrual spotting after a
caesarean section who had a niche with a residual myometrium of
≥3 mm, measured during sonohysterography.
Methods Women were randomly allocated to hysteroscopic niche
resection or expectant management for 6 months.
Main outcome measures The primary outcome was the number of
days of postmenstrual spotting 6 months after randomisation.
Secondary outcomes were spotting at the end of menstruation,
intermenstrual spotting, dysuria, sonographic niche measurements,
surgical parameters, quality of life, women’s satisfaction, sexual function,
and additional therapy. Outcomes were measured at 3 months and,
except for niche measurements, also at 6 months after randomisation.
Results We randomised 52 women to hysteroscopic niche resection
and 51 women to expectant management. The median number of
days of postmenstrual spotting at baseline was 8 days in both groups.
At 6 months after randomisation, the median number of days of
postmenstrual spotting was 4 days (interquartile range, IQR 2–
7 days) in the intervention group and 7 days (IQR 3–10 days) in the
control group (P = 0.04); on a scale of 0–10, discomfort as a result of
spotting had a median score of 2 (IQR 0–7) in the intervention
group, compared with 7 (IQR 0–8) in the control group (P = 0.02).
Conclusions In women with a niche with a residual myometrium
of ≥3 mm, hysteroscopic niche resection reduced postmenstrual
spotting and spotting-related discomfort.
Keywords Abnormal uterine bleeding, caesarean section,
hysteroscopic resection, niche, postmenstrual spotting.
Tweetable abstract A hysteroscopic niche resection is an effective
treatment to reduce niche-related spotting.
Linked article This article is commented on by T El-Toukhy
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10.1111/1471-0528.14823.
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Long-term complaints after caesarean section, such as post-
menstrual spotting, dysmenorrhea, dyspareunia, or chronic
pelvic pain, are frequently described in relation to the pres-
ence of a niche.1–8
A post-caesarean niche is defined as an indentation in the
myometrium at the site of the uterine scar.9 Two independent
prospective cohort studies reported that the presence of a niche
after caesarean section increases the risk of postmenstrual spot-
ting for more than 2 days from 15 to 30%.1,3 Postmenstrual
spotting may be caused by a mechanical outflow problem, with
the retention of menstrual blood in a niche,4,5,7,8 or by the
accumulation of blood because of impaired uterine contrac-
tions at the site of the niche.5 Additionally, newly formed frag-
ile vessels in the niche may play a role in the formation of
blood or fluid in the niche and uterine cavity.
Sonohysterography is reported to measure the niche
more accurately than sonography, with a better delineation
of the niche.1,3,10 Sonohysterography allowed the observa-
tion of a niche in approximately 60% of women 2–
12 months after a caesarean section.1,3,11,12
Hysteroscopic, laparoscopic, or (laparoscopic-assisted)
vaginal niche resections have been developed.13 A hystero-
scopic niche resection is the least invasive of these tech-
niques, but requires a sufficient thick residual myometrium
between the niche and the bladder to prevent bladder
injury.13 A hysteroscopic niche resection can be performed
in different ways: the lower rim (closest to the external cer-
vical os) can be resected to facilitate menstrual outflow
(Figure 1);14–17 both the lower and the upper part of the
niche can be resected;18–21 and this can be combined with
coagulation of the vessels in the niche,16,18–21 or the entire
niche surface.14,15 Previous cohort studies reported a reduc-
tion of postmenstrual spotting in 80–90% of women, and a
reduction in pain in 97% of women, in the absence of
complications.13,22,23 The mean reduction in the number of
days of spotting compared with baseline was reported in
two studies, and varied between 2 and 4 days in 119
women.15,17 Apart from the flawed comparability and lack
of randomisation, the studies did not use validated tools to
measure the outcomes.13–21 We initiated a randomised con-
trolled trial assessing the effect on postmenstrual spotting
of a hysteroscopic niche resection versus no treatment.
Methods
Trial design
We performed a multicentre randomised controlled trial in
11 hospitals that collaborate within the Dutch Consortium
for Healthcare Evaluation and Research in Obstetrics and
Gynaecology. The design and methods of this trial have
been described in the published study protocol.24
Participants
Women with a previous caesarean section who presented
with postmenstrual spotting, and in whom sonohysterogra-
phy had shown a niche with a residual myometrium of at
least 3 mm, were eligible. Postmenstrual spotting was
defined as: (a) two or more days of intermenstrual spot-
ting; or (b) two or more days of brownish discharge at the
end of menstrual bleeding when the total period of
A B
C D
Figure 1. Hysteroscopic niche resection: (A) hysteroscopic view of the niche, with lower rim visible; (B) resection of the lower rim using a
resectoscope; (C) coagulation of the niche surface using a rollerball; (D) hysteroscopic view on the site of the niche after the resection.
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menstrual bleeding exceeds 7 days. Postmenstrual spotting
needed to be present for at least three consecutive months
after the last caesarean section.
A niche was defined as an indentation in the uterine wall
at the site of the caesarean scar with a depth of at least
2 mm, measured during sonohysterography according to a
standardized protocol (Figure S1).24 Exclusion criteria
included being under the age of 18 years, pregnancy, (sus-
pected) malignancies, absence of cyclic bleeding periods
caused by a levonorgestrel intrauterine device (IUD), contin-
uous oral contraceptives or gonadotropin-releasing hormone
(GnRH) agonists, contraindications for spinal or general
anaesthesia, atypical endometrial cells or cervical dysplasia in
cervical cytology, uterine or cervical polyps, submucosal
fibroids, cervical or pelvic infection in the cervical swab, a
hydrosalpinx that communicates with the uterus, or an irreg-
ular cycle (>35 days or with an intercycle variation of
2 weeks or more). The absence of cyclic bleeding as a result
of hormonal treatments was defined in the study protocol
from the start of the study as an exclusion criterion, but was
erroneously not reported in the published study protocol.24
Randomisation
After written informed consent was given, women were ran-
domly allocated to either hysteroscopic niche resection within
1 month (intervention group) or to expectant management
(control group). Randomisation was performed using the
online randomisation program ALEA, using permuted blocks
with a random block size of two or four women, and was strat-
ified for treatment centre. The study was not blinded.
Training of participating gynaecologists
The gynaecologists who participated in the study were
additionally trained and evaluated in their centre in the
measurement of a niche and in performing a hysteroscopic
niche resection by one of the experienced gynaecologists
that performed niche resections in a previous pilot study
(JHU, LVO, WHE, or HBR).24
Interventions
Hysteroscopic niche resection (intervention group)
The resection was performed under continuous sono-
graphic evaluation. The lower rim of the niche, if promi-
nently visible, was resected as described by Chang et al.
and Fabres et al.14,17 The niche surface was superficially
coagulated with the use of a rollerball (Figures 1 and S2).24
Expectant management (control group)
Women in the control group were motivated to refrain
from an additional intervention for 6 months after ran-
domisation. They were encouraged to continue any hor-
monal medication during this period that they had used
before randomisation. In case women wanted to undergo a
hysteroscopic niche resection or to use other additional
therapies before 6 months of follow-up, we left the decision
up to the gynaecologist and the participant, and partici-
pants remained included in the study.
Outcome measures
Women received digital questionnaires at baseline, and at 3
and 6 months after randomization, in which all outcomes
(except for niche measurements) were assessed. Women
were asked to fill out a 1-month menstrual score chart at
baseline, and again at 3 and 6 months after randomisa-
tion.25
The primary outcome was the self-reported number of
days with postmenstrual spotting during a menstrual cycle
at 6 months after randomisation, which was also registered
on a validated menstruation score chart.25
Secondary outcomes were: spotting at the end of the
menstruation; intermenstrual spotting; menstrual-related
pain; discomfort experienced with spotting, as rated on a
visual analogue scale (VAS) of 0–10; sonographic results
(residual myometrium, depth of the niche, presence of
intrauterine fluid); quality of life [Short Form 36 (SF-36)
and EuroQoL5D (EQ-5D)];26,27 women’s satisfaction (five-
point Likert scale); sexual function [Female Sexual Func-
tion index (FSFI)],28 and pain during micturition at 3 and
6 months after randomisation. We also reported additional
therapies at 6 months after randomisation.Women regis-
tered their VAS scores on a scale of 0–10 (i.e. on a line of
10 cm in length) for the various outcomes with 0 as ‘no
discomfort or no pain at all’ and 10 as ‘the most discom-
fort or pain imaginable’.
Three months after randomisation niche depth and
residual myometrium were measured by transvaginal
sonography according to a standardised method.24 Women
were offered to undergo sonohysterography; however, this
was omitted if women refused.
Sample size
At the time of study design, there was only one study
reporting on the reduction in spotting days compared with
baseline. The median reduction was 3.8 days, with an esti-
mated standard deviation of 2.7 days.17 We expected a dif-
ference of 2 days in postmenstrual spotting to be clinically
relevant. Given the lack of studies assessing the clinical rel-
evance of a reduction in the number of spotting days we
chose a conservative cut-off value to reduce the risk of
insufficient power. In order to achieve 90% power to detect
a difference of 2 days of postmenstrual spotting between
the intervention and control group after 6 months of fol-
low-up, with an estimated SD of 2.7 days, a two-sided
alpha of 0.05, and an anticipated drop-out rate of 20%, we
needed to include a total of 100 women.
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Statistical analysis
All analyses were performed using SPSS 22. All tests were
performed two sided and P < 0.05 was considered to indi-
cate statistical significance.
Intention to treat (ITT) analysis
The difference between the two groups after 6 months of
follow-up regarding all continuous variables were analysed
using the Mann–Withney U-test for non-parametric data
(total number of postmenstrual spotting days during one
menstrual cycle, days of spotting at the end of menstrua-
tion, days of intermenstrual spotting, dysmenorrhea, dis-
comfort experienced as a result of spotting, SF-36 domain
scores, EuroQol scores, FSFI scores, niche depth, and resid-
ual myometrium). Baseline characteristics did not statisti-
cally differ between the two groups, and therefore we
decided not to use the planned regression models to adjust
for possible confounding factors.
Fisher’s exact test was used for the binary data, such as
the presence of (midcycle) intrauterine fluid and the pres-
ence of pain during micturition. Satisfaction with the ran-
domised treatment was recoded into a binary outcome
using ‘dissatisfied’ (combining dissatisfied, very dissatisfied,
and neutral) or ‘satisfied’ (combining satisfied and very sat-
isfied), and was analysed with the chi-square test.
Predefined subgroup analyses
To identify a subgroup effect, we tested for an interaction
for the following predefined subgroups: (1) number of
postmenstrual spotting days (total days of spotting per
cycle) at baseline (>25th and >75th percentile); (2) small
versus larger niches at baseline (using a cut-off of the resid-
ual myometrium of 3 mm, 5 mm, and <50% of total
myometrial thickness); (3) one versus more previous cae-
sarean sections.
Additional post hoc analyses
Given the large number of women who became amenor-
rheic during the first 6 months of follow-up as a result of
staring on continuous hormonal medication, or because of
pregnancy, we executed an additional analysis excluding
these women.
We also performed an analysis using the ‘last observation
carried forward’ method for women who received an addi-
tional surgical intervention. We carried data from the last




Between April 2012 and January 2015, 110 women were
eligible and were asked to participate in the trial, of whom
103 women were randomised to the intervention (n = 52)
or expectant management (n = 51) (Figure 2).
ITT analysis
Outcomes were registered for 51 women in the interven-
tion group and for 44 women in the control group after
6 months of follow-up. The reasons for missing data were
the withdrawal of a women’s consent immediately after
randomisation or for loss to follow-up in the control group
(Figure 2). Six women became pregnant during the follow-
up period (three in each group). These women remained
included in our ITT analysis.
Additional post hoc analyses
Women who became amenorrhoic during the first
6 months of follow-up as a result of continuous hormonal
therapy or a pregnancy were excluded from this analysis,
resulting in 41 women in the intervention group and 35
women in the control group.
All 51 women of the intervention group and 44 women
of the control group were included in the ‘last observation
carried forward’ analysis.
Baseline data
Baseline characteristics did not differ statistically between
the two groups (Table 1). The median number of days of
postmenstrual spotting at baseline was 8 days (interquartile
range, IQR 5–12 days) in the intervention group, and
8 days (IQR 6–14 days) in the control group. The median
level of discomfort with spotting was 7.8 (IQR 5.8–8.4) and
8.0 (IQR 6.6–9.0), respectively.
Surgical outcomes (intervention group)
In the intervention group, six women did not undergo the
intervention. Two women had a strong preference for
expectant management after randomisation, one feared the
Figure 2. Flow chart.
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intervention, one feared anaesthesia, one became pregnant
before the intervention, and in one woman the spotting
complaints diminished. This resulted in 45 women receiv-
ing a hysteroscopic niche resection. The surgical outcomes
are presented in Table S1.
Primary outcome
According to the ITT analysis, the median number of days
of postmenstrual spotting at 6 months after randomisation
was 4 days (IQR 2–7 days) in the intervention group ver-
sus 7 days (IQR 3–10 days) in the control group (P = 0.04;
Table 2).
The post hoc analyses excluding women with amenor-
rhoea during follow-up as a result of continuous hormonal
therapy or pregnancy, and the ‘last observation carried for-
ward’ analysis, showed consistent findings with the ITT
analysis (Table S2).
Given the small sample sizes in the various subgroups
we did not execute the intended subgroup analyses.
Secondary outcomes
During the 6 months of follow-up, 13 additional surgical
interventions were performed in the control group versus
none in the intervention group (P < 0.01). Among these 13
Table 1. Baseline characteristics
Characteristic Intervention (n = 52) Control (n = 49)
Age (years) 36.6  5.0 36.9  4.9
Body mass index (kg/m2) 24.4  4.3 24.9  4.2
Smoking 9 (17.3%) 11 (22.9%)
Use of anticoagulants 0 1 (2.1%)
Use of tranexamic acid 0 1 (2.0%)
Parity 2 (1–2) 2 (1–3)
Number of caesarean sections 1 (1–2) 2 (1–3)
Time since last caesarean section (months) 55.5 (27.8–80.3) 39 (23–80)
History of uterine surgery
Curettage 2 (3.8%) 1 (2.0%)
Transcervical resection polyp 1 (1.9%) 1 (2.0%)
Transcervical resection fibroid 0 0
Fibroid enucleation 1 (1.9%) 0
Wish to conceive 18 (35.3%) 12 (25%)
Fertility treatment after last caesarean section 5 (9.6%) 3 (6.3%)
Hormonal contraception
Oral contraception 14 (26.9%) 7 (14.3%)
Levonorgestrel intrauterine device 1 (1.9%) 1 (2.0%)
Nuvaring 1 (1.9%) 0
Bleeding/micturition characteristics
Duration of bleeding complaints (months) 36.5 (16–60) 35 (14–56)
Total days of spotting* 8 (5–12) 8 (6–14)
Spotting end of menstruation 4 (2–8) 6 (3–11)
Intermenstrual spotting 3 (0–5) 2 (0–5)
Discomfort from spotting (0–10) 7.8 (5.8–8.4) 8.0 (6.6–9.0)
Dysmenorrhea (0–10) 5.4 (0–7) 7.0 (0–8.2)
Daily pain during micturition 4 (7.7%) 6 (12.2%)
Ultrasound findings
Residual myometrium (mm) 4.0 (3.4–6.0) 4.5 (3.6–6.6)
Depth niche (mm) 6.0 (4.0–8.1) 6.0 (4.2–7.4)
Intrauterine fluid 11/51 (21.6%) 4/45 (8.9%)
Quality of life and sexual function
SF-36 physical component summary score 53.9 (47.7–57.8) 50.4 (39.7–56.9)
SF-36 mental component summary score 51.7 (43.7–55.6) 49.4 (36.0–53.7)
EuroQol total score 0.84 (0.78–1.0) 0.83 (0.69–0.85)
FSFI total score 18.3 (15.3–21.5) 15.6 (13.4–20.5)
Data are reported as mean  standard deviation, as n (valid percentage), or as median (interquartile range, IQR).
No baseline characteristics differed statistically between the two groups.
*Total days of spotting = the sum of the number of days spotting at the end of the menstruation and the number of days of intermenstrual
spotting (postmenstrual spotting).
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women, nine underwent hysteroscopic niche resection, two
underwent endometrial ablation, one underwent transcervi-
cal resection of a fibroid (that was missed at baseline), and
one underwent laparoscopic hysterectomy because of per-
sisting symptoms. The number of additional medical hor-
monal therapies did not differ between the two groups
(Table S3).
At 6 months after randomisation, the median discomfort
with spotting was 2.0 (IQR 0–6.8) versus 6.9 (IQR 0.4–8.0)
(on a VAS of 0–10) in the intervention and control groups,
respectively (P = 0.02). Other menstrual characteristics and
number of women with pain during micturition did not
differ statistically between the two groups (Table 2). Post-
menstrual spotting did not differ after 3 months of follow-
up, with 6 days (IQR 2–9 days) reported in the interven-
tion group and 7 days (IQR 2–10 days) reported in the
control group (P = 0.54).
After 6 months of follow-up, quality of life measured
with EuroQol and the total physical component score of
the SF-36 did not differ statistically between the two
groups. The total mental component score of the SF-36
was slightly higher in the intervention group (52.6, IQR
47.0–56.9) than in the control group (50.0, IQR 44.5–54.2)
(P = 0.05; Table 2). More women in the intervention
group were (very) satisfied with the randomised treatment
(71.1%) in comparison with the control group (37.5%);
(RR 2.2; 95% CI 1.23–3.80).
Transvaginal sonography 3 months after randomisation
was performed in 36 out of 51 women (70.6%) in the
intervention group, and in 23 out of 44 women (52.3%) in
the control group. The depth of the niche and the thick-
ness of the residual myometrium did not differ statistically
between the two groups after 3 months of follow-up, and
within the two groups in comparison with baseline
(Table S4). Niche depth and residual myometrium were
evaluated with sonohysterography in only 24 women
(47.1%) of the intervention group and 13 women (29.5%)
of the control group, mainly because women were not
motivated to undergo a second sonohysterography.
Complications
No complications occurred during the niche resection. One
woman developed fever and lower abdominal pain after the
intervention, which was diagnosed as pelvic inflammatory
disease and treated with antibiotics. No complications
occurred in the control group.
Discussion
Main findings
Hysteroscopic niche resection reduced the median number
of days of postmenstrual spotting by 3 days after
6 months of follow-up compared with expectant manage-
ment, and by 4 days compared with baseline. Discomfort
related to spotting (on a VAS of 0–10) was five points
lower in the intervention group in comparison with the
control group after 6 months of follow-up. After the
intervention, the median number of days of discomfort
related to spotting reduced from eight at baseline to two
after 6 months of follow-up. More women were (very)
satisfied in the intervention group compared with the
control group, and more surgical additional interventions
were performed in the control group. The residual myo-
metrium using transvaginal ultrasonography at 3 months
did not change in comparison with baseline or with the
control group.
Table 2. Bleeding characteristics and quality of life after 6 months of follow-up, by intention-to-treat analysis
Outcomes Intervention n = 51 Control n = 44 P
Bleeding/micturition characteristics
Total days of spotting* 4 (2–7) 7 (3–10) 0.04
Spotting at the end of the menstruation 3 (2–5) 5 (2–8) 0.13
Intermenstrual spotting 0 (0–0) 0 (0–3) 0.15
Discomfort from spotting (0–10) 2.0 (0–6.8) 6.9 (0.4–8.0) 0.02
Dysmenorrhea (0–10) 3.0 (0–6.2) 4.3 (0–7.3) 0.37
Daily pain during micturition 2 (4.7%) 3 (7.9%) 0.67
Quality of life and sexual function
SF-36 physical component summary score 53.1 (45.4–58.7) 52.1 (46.6–57.7) 0.67
SF-36 mental component summary score 52.6 (47.0–56.9) 50.0 (44.5–54.2) 0.05
EuroQol total score 0.84 (0.81–1.0) 0.83 (0.72–1.0) 0.33
FSFI total score 13.5 (9.8–21.6) 15.1 (10.0–21.3) 0.61
Data are reported as n (valid percentage) or as median (IQR). Analyses are by intention to treat.
*Total days of spotting = the sum of the number of days spotting at the end of the menstruation and the number of days of intermenstrual
spotting (postmenstrual spotting).
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Strengths and limitations
Strengths
This trial is the first randomised controlled trial to evaluate
the effectiveness of a hysteroscopic niche resection versus
expectant management in women with niche-related post-
menstrual spotting. Randomisation was performed with
allocation concealment through a web-based randomisation
program, which reduced the chance for selection bias. The
surgeons were trained and assessed in their execution of
this new intervention in order to perform it in a standard-
ised manner. All questionnaires were completed without
interference of care-providers, thereby reducing the risk of
socially acceptable answers. We used validated question-
naires and standardised methods for the measurement of
niche characteristics.29
Limitations
The study could not be blinded for the participant or for
the surgeon, and therefore the Hawthorne effect cannot be
excluded;30 however, knowing the allocation of the inter-
vention is part of real life, and its contribution to the (per-
ceived) effectiveness of the intervention could be taken into
account.
The hysteroscopic resection was executed later than
planned in the protocol: 55% of women in the intervention
group received it in the second or third month after ran-
domisation. For this reason we considered the data after
3 months of follow-up as not reliable, because this moment
of follow-up would be still in the healing phase after the
surgical procedure.
Experience with performing the intervention and the num-
ber of included women differed between the various centres,
and therefore the effect of a learning curve cannot be excluded.
To reduce the effect of a learning curve on outcomes between
the study groups, women were stratified per centre.
Quality of life was only measured using generic question-
naires; these may be not responsive enough to measure dif-
ferences in discomfort as a result of spotting. Disease-specific
validated questionnaires have not yet been developed.
The number of women who withdrew immediately after
randomisation or who were lost to follow-up was particu-
larly high in the control group. This should be taken into
account interpreting the results of the ITT analysis. Accord-
ing to our sample size calculation, however, we maintained
sufficient power despite these losses.
Many additional medical therapies were applied during
the 6 months of follow-up in both groups, and many addi-
tional surgical interventions were used in the control
group, which might have biased our primary outcome in
the ITT analysis. For this reason we performed an addi-
tional analysis excluding all women with amenorrhea,
which showed consistent findings with the ITT analysis;
however, the required number for adequate power was not
reached in this analysis. Median spotting at baseline was
particularly high (10 days) in controls who underwent
additional surgical therapy. This may explain the reduction
in spotting in the entire control group at follow-up, com-
pared with baseline. This may have resulted in an underes-
timation of the effect in our study. This is underlined by
the fact that the effect of the intervention became more
pronounced in the additional analysis using the last obser-
vation carried forward.
Interpretation
The reduction in the number of postmenstrual spotting
days after 6 months of follow-up is in line with previous
publications on hysteroscopic niche resection. The mean
reported reduction in spotting in one prospective and one
retrospective cohort study varied between 2 and 4 days.15,17
Two recent non-comparative studies in 144 women
reported a resolution of spotting in 80% of women; how-
ever, a reduction in the number of days of spotting was
not reported.22,23
Although our trial reported a modest reduction in post-
menstrual spotting, the reduction in discomfort related to
spotting was substantial. This suggests that even a modest
reduction of some days is relevant for women with these
symptoms, although it did not result in a difference in gen-
eric quality of life.
Proximal resection of the niche may in theory cause cer-
vical incompetence in a subsequent pregnancy. In addition,
we expected the niche resection to increase the size of the
niche and wanted to prevent any unneeded enlargement in
volume. Although we did not find a reduction in the resid-
ual myometrium in our study, we need to interpret these
results with caution, because not all women showed up for
the sonographic measurements at follow-up. Additionally,
we did not measure the length and volume of the niche,
which in theory may enlarge after resection (of the lower
rim) of the niche.
A hysteroscopic niche resection should only be per-
formed if the residual myometrium between the niche and
the bladder is sufficiently thick to prevent bladder injury.
The cut-off value of the residual myometrium in various
studies varies between 2.5 and 4.0 mm, as measured using
sonohysterography.13,22,23
We have only included women with relatively small
niches (≥3 mm), and thus the outcomes should not be
extrapolated to women with large niches. In women with a
large niche (with residual myometrium of <3 mm) with
severe symptoms and desiring to conceive, a laparoscopic
niche resection may be considered. Given the limited stud-
ies evaluating this method and the lack of randomised trials
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this intervention should only be offered in a research
setting.
It is important to realise that not all niches cause symp-
toms. Treatment should only be performed in order to
reduce symptoms, and thus niches without symptoms
should not be treated. Although oral contraceptives or
levonorgestrel IUD are less invasive therapeutic options,
and might therefore be offered first, their effectiveness for
this indication has not yet been proven. In women with an
actual desire to conceive or with contraindications for hor-
mone treatment, this is not an option. Given the reported
reduction in the number of spotting days and discomfort
in favour of the hysteroscopic niche resection in our trial,
it may be considered in symptomatic women with a niche
with sufficient residual myometrium (≥3 mm).
Every woman must tradeoff the limited reduction of
spotting against the burden of the procedure. In addition,
we need to inform women about the uncertainty of
whether the reduction in spotting will persist in the longer
term, and it is not expected to affect their generic quality
of life. The same accounts for the unknown effect of a hys-
teroscopic niche resection on the risk for scar rupture in
labour, pregnancy implantation involving the scar, and
related morbidly adherent placenta or cervical incompe-
tence in future pregnancies.
Future perspectives
Long-term follow-up is needed to evaluate the sustainabil-
ity of a hysteroscopic niche resection and the cost-effective-
ness. Larger studies are needed to evaluate the effect of a
hysteroscopic niche resection on reproductive outcomes of
subsequent pregnancies, including possible cervical incom-
petence.
Future preferably randomised studies are needed to eval-
uate the effectiveness of hormones compared with hystero-
scopic niche resection.
Conclusion
In conclusion, a hysteroscopic niche resection reduces post-
menstrual spotting, and the discomfort from spotting,
compared with expectant management after 6 months of
follow-up in women with a niche with a residual myome-
trium of at least 3 mm.
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